Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05925101 · ClinicalTrials.gov registry record · NA

Basic and Applied Research on Extinction Bursts

A NA study of Aggression and Problem Behavior, sponsored by Rutgers, The State University of New Jersey.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT05925101: Recruiting NA study of Aggression and Problem Behavior, sponsored by Rutgers, The State University of New Jersey.

NCT05925101 is a NA study of Aggression and Problem Behavior that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 40 participants, below the 153-participant average among 21 other Aggression trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05925101, a NA study of Aggression and Problem Behavior, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Although highly effective, treatments like FCT include extinction, which can have adverse side effects. The extinction burst, an increase in the frequency or intensity of destructive behavior at the start of treatment, is the most common side effect of extinction, and can increase the risk of harm to the patient and others. The goal of the current study is to evaluate the prevalence of extinction bursts when various parameters of reinforcement (i.e., rate, magnitude, quality) are manipulated.

Primary Outcome

The investigators will collect continuous, direct-observation measures of destructive behavior throughout all phases of the study. They will compare rates of destructive behavior during the first three sessions of each treatment condition to baseline.

Interventions

  • BEHAVIORAL Extinction-only condition
  • BEHAVIORAL Rate-drop condition
  • BEHAVIORAL Rate-hold condition
  • BEHAVIORAL Magnitude-drop condition
  • BEHAVIORAL Magnitude-hold condition

Study Locations (1)

New Jersey

  • Children's Specialized Hospital-Rutgers University Center for Autism Research, Education, and Services - Somerset

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-07-07
Est. Completion 2028-05-31
Phase NA

What NCT05925101 shows while recruiting

NCT05925101 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 153-participant average among 21 other Aggression trials with a reported enrollment target (74% lower).

The record links to 3 conditions, with Aggression appearing as the primary indexed condition, and to 5 interventions - of which Extinction-only condition is the first listed.

NCT05925101 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT05925101 about?

NCT05925101 is a clinical study titled "Basic and Applied Research on Extinction Bursts". Although highly effective, treatments like FCT include extinction, which can have adverse side effects. The extinction burst, an increase in the frequency or intensity of destructive behavior at the start of treatment, is the most common side effect of extinction, and can increase the risk of harm t...

What is the current status of trial NCT05925101?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2023-07-07. Estimated completion is 2028-05-31.

What conditions does trial NCT05925101 study?

This clinical trial studies the following conditions: Aggression, Problem Behavior, Self-Injury.

What interventions are being tested in trial NCT05925101?

The interventions under investigation include: Extinction-only condition (BEHAVIORAL), Rate-drop condition (BEHAVIORAL), Rate-hold condition (BEHAVIORAL), Magnitude-drop condition (BEHAVIORAL), Magnitude-hold condition (BEHAVIORAL).

Who is sponsoring clinical trial NCT05925101?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05925101 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aggression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05925101's enrollment target sits among peer trials

40 13th of 21 higher than 7 of 21 other Aggression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aggression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05925101, the US trial registry maintained by the National Library of Medicine. NCT05925101 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.